Decoy Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
DCOY Nasdaq 2836 decoytx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Decoy Therapeutics Inc.

Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board - May 26th, 2026 6:15 am
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston - Apr 27th, 2026 6:45 am
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline - Apr 9th, 2026 6:36 am
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 - Apr 6th, 2026 7:15 am
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - Apr 2nd, 2026 7:00 am
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform - Mar 11th, 2026 6:30 am
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split - Mar 5th, 2026 6:30 am
Decoy Therapeutics Joins Webull Corporate Connect Service Platform - Feb 11th, 2026 7:00 am
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Feb 5th, 2026 7:15 am
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Feb 4th, 2026 7:02 am
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - Jan 13th, 2026 6:15 am